New hope for advanced liver cancer? early trial launches

NCT ID NCT04906434

Recruiting now Disease control Sponsor: Abbisko Therapeutics Co, Ltd Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times

Summary

This early-stage study tests a new drug called ABSK-011 in people with advanced solid tumors, especially liver cancer. The main goal is to check the drug's safety and how the body processes it. About 200 participants will take the drug by mouth, and researchers will monitor side effects and drug levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Tsinghua Changgung Hospital
RECRUITING

Beijing, Beijing Municipality, China

Contact

Contact
Chongqing Cancer Hospital
RECRUITING

Chongqing, Chongqing Municipality, China

Contact

Contact

Contact
First Affiliated Hospital of Henan University of Science and Technology
COMPLETED

Luoyang, Henan, China
Fujian Provincial Cancer Hospital
COMPLETED

Fuzhou, Fujian, China
General Hospital of Ningxia Medical University
COMPLETED

Yinchuan, Ningxia, China
Guangxi Zhuang Autonomous Region People's Hospital
COMPLETED

Nanning, Guangxi, China
Harbin Medical University Cancer Hospital
RECRUITING

Haerbin, Heilongjiang, China

Contact

Contact
Henan Cancer Hospital
COMPLETED

Zhengzhou, Henan, China
Hubei Cancer Hospital
COMPLETED

Wuhan, Hubei, China
Hunan Cancer Hospital
COMPLETED

Changsha, Hunan, China
Hunan Provincial People's Hospital
WITHDRAWN

Changsha, Hunan, China
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States

Contact Email: •••••@•••••
Jinan Central Hospital
COMPLETED

Jinan, Shandong, China
Linyi Cancer Hospital
COMPLETED

Linyi, Shandong, China
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Email: •••••@•••••
Mayo Clinic
RECRUITING

Phoenix, Arizona, 85054, United States

Contact Phone: •••-•••-••••
Mayo Clinic
RECRUITING

Jacksonville, Florida, 32224, United States

Contact Phone: •••-•••-••••
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States

Contact Phone: •••-•••-••••
Mianyang Central Hospital
RECRUITING

Mianyang, Sichuan, China

Contact

Contact
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

Contact Email: •••••@•••••

Contact
Nation Taiwan University Hospital
COMPLETED

Taipei, Taiwan
National Cheng Kung University Hospitals
COMPLETED

Tainan, Taiwan
Ningbo Huamei Hospital, University of Chinese Academy of Sciences
WITHDRAWN

Ningbo, Zhejiang, China
Shengjing Hospital of China medical university
COMPLETED

Shenyang, Liaoning, China
Sun Yat Sen Memorial Hospital
COMPLETED

Guangzhou, Guangdong, China
Suzhou University Affiliated Second Hospital
COMPLETED

Suzhou, Jiangsu, China
The Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army
WITHDRAWN

Beijing, Beijing Municipality, China
The First Affiliated Hospital of Bengbu Medical College
COMPLETED

Bengbu, Anhui, China
The First Affiliated Hospital of Xi'an Jiaotong University
WITHDRAWN

Xian, Shanxi, China
Tonghua Central Hospital
COMPLETED

Tonghua, Jilin, China
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
RECRUITING

Wuhan, Hubei, China

Contact

Contact
Weifang People's Hospital
COMPLETED

Weifang, Hebei, China

Conditions

Explore the condition pages connected to this study.

ADVANCED LIVER CANCER